TEVA - Embedded Expectations Analysis - 2020 10 08
Teva Pharmaceutical Industries Limited (TEVA:USA) currently trades below recent averages relative to UAFRS-based (Uniform) earnings, with an 11.3x Uniform P/E, implying bearish expectations for the firm. Furthermore, management may be concerned about the potential of their products, their ability to meet operating income margin outlook, and their venture with TakedaSpecifically, management may lack confidence in their ability to sustain free cash flow, meet their operating income margin target of 28%, and sustain Europe revenues. Moreover, they may have concerns about further weakness in COPAXONE and the potential of their biosimilar products in partnership with Alvotech. They may also have concerns about their ability to continue to grow their TRUXIMA business, as well as their digital, products, and respiratory space. Management may also be exaggerating the potential of AJOVY, have concerns about the arthropathies increase in Fasinumab, and the potential of their business venture with Takeda. Furthermore, they may lack confidence in their ability to continue improving AUSTEDO performance, become a leader in generics and biopharmaceuticals, and sustain GAAP net income
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.